Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for Mounjaro ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

Mounjaro and Zepbound are by far Lilly's fastest-growing ... The company is well diversified and is witnessing notable success in areas outside of the GLP-1 realm. Verzenio's performance in ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.